LeukoCom specializes in the development of murine monoclonal antibodies targeting CEACAM, as well as the establishment of stable cell lines expressing CEACAM proteins. Founded in 2012 by Dr. Bernhard Singer and colleagues, the company began an early collaboration with CancerTools, which now distributes our products.

We are open to new partnerships to further advance our antibodies in research projects and the biotech industry.